摘要
We thank Tapley et al. for their response [1] to our recent editorial [2]. We hoped that our work might give anaesthetists pause to consider, and take a more meticulous approach to quantifying, the environmental impacts of their practice; it is clear that Tapley et al. have done so concerning total intravenous anaesthesia (TIVA). We agree that TIVA is not without waste and resource implications. Tapley et al.'s calculations usefully add to what is known about this subject. However, calculations comparing the relative environmental impacts of TIVA and inhalational agents require a universal comparator, such as life-cycle greenhouse gas emission CO2 equivalents (CO2e). In their excellent analysis from 2012, Sherman et al. [3] summated the manufacturing, packaging, transport, drug delivery and waste management CO2e (grams) of four general anaesthetic agents. Even after assuming that 50% of propofol is wasted and excluding the environmental effects of waste inhalational agents themselves, they calculated that the CO2e for isoflurane, sevoflurane and desflurane were approximately 20, 40 and 70 times greater, respectively, than for propofol-based TIVA on a minimum alveolar concentration-equivalent basis. We suspect there is considerable error in scaling up the waste estimated from a model of single practice to national levels. Tapley et al. have modelled a 'worst case scenario', by assuming that an anaesthetist only administers TIVA without supplementary, balanced regional anaesthesia, without anaesthesia downtime, throughout their whole career, to healthy young men only and at high target plasma concentrations. Although their calculations concur with our aim of giving anaesthetists pause to consider the environmental effects of their practice, their figures are likely an overestimate of the comparative environmental impact of TIVA. We suggest that their calculations model only a small fraction of the environmental impact of contemporary general anaesthetic practice, in which 92% of approximately 2.75 million annual UK general anaesthetics involve inhalational maintenance [4], vented directly into the atmosphere, despite new technology for volatile capture and extraction (which has always been 'underway', but never quite makes it into clinical practice). The message in our editorial was not that TIVA is particularly efficient or 'green', but that inhaled anaesthetic agents are uniquely problematic and that continuing to accept their role as the 'standard' approach for the maintenance of general anaesthesia is unjustifiable in the context of the ongoing climate crisis. We agree that balance and integration are cornerstones of anaesthetic practice, but technological advance renders redundant modalities obsolete; general anaesthesia has remained possible even though we no longer use ether, halothane, enflurane or indeed, thiopentone (for the most part). These were superseded for clinical reasons, but anaesthetists have to remember that responsibility for their clinical practice extends beyond the patient in front of them and into the wider public health arena [5]. There was considerable professional protest during the phasing out of these obsolete agents, until the use of newer agents became normal. Serendipitously, we wonder whether the COVID-19 crisis will hasten the abandonment of inhalational anaesthesia, as anaesthetists have had to become more familiar with administering intravenous sedation in the critical care setting, and (unsedated) regional anaesthesia in the operating theatre [6]. We acknowledge the authors' argumentum ad consequentiam that abandoning inhalational agents will have unintended consequences, but suggest that these are far more likely to be beneficial for patients and the environment than they are harmful. The clock is ticking.